Bristol Myers Squibb Resumes Radiopharmaceutical Phase 3 Trial Following Isotope Shortage

1. Trial Resumption: Bristol Myers Squibb has restarted recruitment for its lead radiopharmaceutical Phase 3 trial after a pause due to an isotope shortage.
2. Isotope Shortage: The trial was halted due to a shortage of actinium-225, a rare radioactive isotope crucial for the experimental treatment RYZ101.
3. Trial Details: The Phase 3 trial, known as ACTION-1, is assessing RYZ101 for treating somatostatin receptor (SSTR) expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
4. Enrollment Delay: New patient enrollment was paused in June 2024 but is now set to resume in the third quarter of 2024.
5. Readout Delay: The trial's readout has been delayed by one year due to the isotope shortage.
6. Radiopharmaceutical Industry: The incident highlights supply chain challenges in the radiopharmaceutical industry, which is experiencing significant growth and investment.